📚 Guideline basis
Baumgartner H, et al. EACVI/ASE Focused Update on Aortic Valve Stenosis (JASE 2017;30:372–92); 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease (Eur Heart J 2025;46:4635–), including the integrated severity pathway with CT calcium scoring and the lowering of the TAVI age threshold from 75 to 70 years; 2020/2021 ACC/AHA valvular heart disease guideline.
Pathophysiology & Mechanisms
Fixed obstruction to LV ejection generates a systolic pressure gradient. The ventricle compensates by concentric hypertrophy, which normalises wall stress by the Laplace relation (σ ∝ Pr/2h) at the cost of four consequences that define the ICU physiology:
- Diastolic dysfunction. The hypertrophied, fibrotic ventricle has a steep end-diastolic pressure–volume relationship. Small volume increments produce large rises in LVEDP and pulmonary oedema; volume depletion produces disproportionate falls in stroke volume.
- Atrial dependence. Atrial contraction contributes up to 30–40% of end-diastolic volume in severe AS. Loss of sinus rhythm can precipitate acute decompensation independent of any change in the valve.
- Subendocardial ischaemia without coronary disease. Increased muscle mass, elevated LVEDP compressing subendocardial vessels, and shortened diastolic perfusion time combine to produce demand ischaemia at normal coronary anatomy. Tachycardia is doubly harmful — it shortens both filling and coronary perfusion time.
- Fixed cardiac output. The ventricle cannot augment stroke volume across the obstruction. Systemic vasodilatation therefore produces hypotension that cannot be compensated, and hypotension reduces coronary perfusion pressure into a hypertrophied ventricle — a self-reinforcing spiral that is the mechanism of sudden decompensation and arrest in these patients.
Diagnostic Synthesis
Severity criteria
Parameter | Mild | Moderate | Severe | Very severe |
Peak velocity, m/s | 2.6–2.9 | 3.0–3.9 | ≥ 4.0 | ≥ 5.0 |
Mean gradient, mmHg | < 20 | 20–39 | ≥ 40 | ≥ 60 |
AVA, cm² | > 1.5 | 1.0–1.5 | ≤ 1.0 | — |
AVA index, cm²/m² | > 0.85 | 0.60–0.85 | ≤ 0.6 | — |
Dimensionless index | > 0.50 | 0.25–0.50 | < 0.25 | — |
AVA = (0.785 D²_LVOT × VTI_LVOT) / VTI_AV
DI = VTI_LVOT / VTI_AVThe dimensionless index is the ICU parameter of choice when the LVOT diameter is difficult to measure: it cancels the diameter entirely and is therefore immune to the squared-error problem that dominates AVA calculation.
Mean gradient is obtained by machine integration of 4v² across the ejection envelope — it is not 4 × (mean velocity)², and it cannot be derived by hand from the peak velocity.
The four discordant patterns
Discordance between a small AVA and a low gradient is common — present in roughly a third of severe AS by area — and resolving it is the central diagnostic task.
Pattern | LVEF | SVI | Gradient | AVA | Interpretation |
High-gradient severe AS | Any | Any | ≥ 40 mmHg | ≤ 1.0 cm² | Severe. No further testing needed |
Classical low-flow, low-gradient | < 50% | < 35 mL/m² | < 40 mmHg | ≤ 1.0 cm² | Needs dobutamine stress echo |
Paradoxical low-flow, low-gradient | ≥ 50% | < 35 mL/m² | < 40 mmHg | ≤ 1.0 cm² | Small, hypertrophied, stiff ventricle; check for measurement error, hypertension, AF, MR, and cardiac amyloidosis |
Normal-flow, low-gradient | ≥ 50% | ≥ 35 mL/m² | < 40 mmHg | ≤ 1.0 cm² | Usually moderate AS with LVOT measurement error |
Before accepting a discordant result, exclude measurement error first: an underestimated LVOT diameter is the commonest cause of a spuriously small AVA, and an LVOT sample volume contaminated by the transvalvular jet is the commonest cause of a spuriously high VTI ratio.
Dobutamine stress echocardiography for classical LFLG AS
Low-dose protocol, typically 5 µg/kg/min increments to a maximum of 20 µg/kg/min, stopping for symptoms, a heart rate rise > 10–20 beats/min above baseline or > 100/min, arrhythmia, or hypotension.
Response | Definition | Interpretation |
Flow (contractile) reserve present | Stroke volume rises ≥ 20% | The test is interpretable |
True severe AS | AVA remains ≤ 1.0 cm² while mean gradient rises to ≥ 40 mmHg or Vmax to ≥ 4 m/s | Valve is the problem |
Pseudo-severe AS | AVA increases to > 1.0–1.2 cm² with little gradient rise | Myocardium is the problem; the valve opened when flow rose |
No flow reserve | SV rise < 20% | Test uninterpretable; poor prognosis; adjudicate with CT calcium score |
Projected AVA at a standardised flow rate of 250 mL/s can be computed to interpret intermediate responses.
Dobutamine stress echocardiography is not a routine ICU test. In an already shocked patient the physiology is uninterpretable and the risk is real. Its place is in the stabilised patient in whom the surgical decision hinges on the answer.
CT calcium scoring — the flow-independent adjudicator
The 2025 ESC/EACTS pathway incorporates CT aortic valve calcium score with sex-specific thresholds: > 2000 AU in men, > 1200 AU in women supports severe AS. Because it measures anatomy rather than flow, it is the appropriate tiebreaker in exactly the low-flow, arrhythmic, vasoactive-supported patients in whom Doppler is least reliable.
Pressure recovery
Doppler measures the maximal instantaneous gradient at the vena contracta; some kinetic energy is reconverted to pressure downstream, so catheter-measured peak-to-peak gradients are lower. The discrepancy is clinically relevant when the ascending aorta is < 3 cm in diameter. The energy loss index corrects for this:
ELI = (AVA × A_a) / ((A_a - AVA) × BSA)where A_a = ascending aortic cross-sectional area at the sinotubular junction. ELI ≤ 0.6 cm²/m² indicates severe AS.
Acquisition — where errors arise
Step | Requirement | Failure mode |
LVOT diameter | Zoomed PLAX, mid-systole, harmonics off, inner-to-inner, 0.5–1.0 cm below the annulus | Squared error; a 2 mm error on a 20 mm LVOT produces a 21% AVA error |
LVOT VTI | PW at the same level the diameter was measured; a crisp, narrow, early-peaking envelope | Contamination by the transvalvular jet inflates VTI and falsely enlarges AVA |
AV VTI | CW from multiple windows — apical, right parasternal, suprasternal, subcostal; use a dedicated non-imaging (Pedoff) probe | Omitting the right parasternal window under-grades AS in a meaningful minority of patients |
Mean gradient | Trace the dense modal envelope | Tracing the outer spectral spray inflates the gradient |
SVI | Always reported | Without it, gradients are uninterpretable |
ICU-Specific Limitations
Confounder | Effect | Response |
Sepsis / high output | Gradients rise at unchanged anatomy — pseudo-severe | Report SVI; reassess after resolution |
Low output / shock | Gradients fall — true severe AS under-called | Use AVA, DI and CT calcium; do not rely on gradient |
Atrial fibrillation | Beat-to-beat variation | Average ≥ 5–10 beats |
Tachycardia | Shortened ejection lowers VTI and gradient | Report heart rate; rate control is therapeutic |
Systemic hypertension | Increases total afterload and reduces the transvalvular gradient | Note the blood pressure; severity may be under-called |
Concomitant severe MR | Reduces forward flow, lowering the gradient | Grade both lesions together |
Cardiac amyloidosis | Overrepresented in paradoxical LFLG AS; low-voltage ECG, apical sparing on strain, increased wall thickness | Consider it explicitly in this phenotype |
Therapeutic Logic — managing severe AS in the ICU
The haemodynamic goals invert standard shock management.
Goal | Rationale | Practical |
Maintain systemic vascular resistance | Coronary perfusion of a hypertrophied ventricle depends on aortic diastolic pressure; the fixed obstruction prevents compensation for vasodilatation | Noradrenaline or phenylephrine early; avoid vasodilators, avoid propofol boluses at induction |
Maintain sinus rhythm | Atrial contribution up to 30–40% of EDV | Early cardioversion for new AF; magnesium and amiodarone as appropriate |
Control heart rate (60–80/min) | Preserves filling and coronary perfusion time | Avoid tachycardia; treat pain, fever, hypovolaemia |
Maintain preload | Steep diastolic pressure–volume relationship in both directions | Judicious volume; avoid aggressive diuresis and avoid large boluses |
Avoid pure inotropes and vasodilators | Increase gradient and reduce perfusion pressure | Dobutamine is used only for the specific low-flow, low-EF phenotype with careful monitoring |
Avoid intra-aortic balloon pump as a reflex | Reduces afterload but does not relieve fixed obstruction; contraindicated with significant coexisting AR | Consider only in specific bridging contexts |
For the crashing patient with critical AS, the definitive therapy is relief of obstruction. Emergency balloon aortic valvuloplasty is a bridge to TAVI or surgery in cardiogenic shock. The 2025 ESC/EACTS guidelines lowered the age threshold favouring TAVI in anatomically suitable tricuspid AS from 75 to 70 years, substantially expanding the eligible population and making early Heart Team involvement appropriate for ICU patients previously considered surgical-only or non-candidates.
🛑 Critical pitfall: Treating hypotension in severe AS with fluid and inotropes while omitting a vasopressor. Falling diastolic pressure reduces coronary perfusion to a hypertrophied, ischaemic ventricle and accelerates the spiral toward arrest.
🛑 Critical pitfall: Tracing the aortic jet envelope while intending to measure LVOT VTI. This inflates stroke volume, enlarges the calculated AVA, and converts severe AS into "moderate".
🛑 Critical pitfall: Accepting a low gradient as reassurance in a shocked patient. In low flow, severe AS routinely produces gradients well under 40 mmHg.
- 💡 Clinical pearl: Dimensionless index < 0.25 is severe AS regardless of what the LVOT diameter measurement did. When windows are poor, this is the number to trust.
- 💡 Clinical pearl: Always interrogate the right parasternal window with a non-imaging probe. It yields the highest velocity in a meaningful minority of patients, and missing it under-grades the lesion.
- 💡 Clinical pearl: Paradoxical low-flow, low-gradient AS with a small, thick-walled ventricle and preserved EF should prompt a deliberate look for cardiac amyloidosis — the association is well described and changes the entire management plan.
References
- Baumgartner H, Hung J, Bermejo J, et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the EACVI and the ASE. J Am Soc Echocardiogr 2017;30:372–92.
- ESC/EACTS. 2025 Guidelines for the management of valvular heart disease. Eur Heart J 2025;46:4635–.
- Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease. Circulation 2021;143:e72–227.
- Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J 2016;37:2645–57.
- Zoghbi WA, Jone PN, Chamsi-Pasha MA, et al. Guidelines for the evaluation of prosthetic valve function with cardiovascular imaging. J Am Soc Echocardiogr 2024;37:2–63.